The reductions of inflammatory infiltrate in the kidney interstitium and reduced tubulointerstitial fibrosis noted with SGLT2 inhibitor therapy in preclinical models suggests a further possible mechanism to reduce susceptibility to AKI [90, 91]. Here, SLC5A2 is linked to acute kidney injury.